NRx Pharmaceuticals, Inc.
NASDAQ:NRXP · NASDAQ Global Market
-$0.08 today
Vol 0.55M · Avg 1.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
179.6%
avg -35.5%
ROIC
106.0%
avg 72.4%
ROA
-220.9%
avg -391.0%
Analysis
ROE is currently the strongest return metric at 179.6% versus its period average of -35.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan C. Javitt | Co-Founder, Chairman & CEO | $846,774.00 | — | 69 | $125,000.00 | 0.72% |
Michael S. Abrams | CFO & Treasurer | $363,083.00 | — | 56 | $0.00 | <0.01% |
Riccardo Panicucci | Chief Manufacturing & Technology Officer | $240,000.00 | — | 64 | — | — |
Dennis K. McBride | Chief Strategy Officer & Director | $38,462.00 | — | 71 | $25,000.00 | 0.14% |
Hervé Perron | Chief Scientist | — | — | 67 | — | — |
Philip T. Lavin | Chief Methodologist | — | — | 79 | — | — |
Glenn Tyson | Chief Commercial Officer | — | — | — | — | — |
Joseph Casper | Chief Operating Officer | — | — | 75 | $0.00 | <0.01% |
Joshua C. Brown | Chief Medical Innovation Officer | — | — | — | $9.63M | 55.74% |
Suzanne Messere | Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$215.30M
Century Therapeutics, Inc.
NASDAQ:IPSC
$194.78M
Equillium, Inc.
NASDAQ:EQ
$99.82M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
Senti Biosciences, Inc.
SNTI
$25.24M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages NRXP?
NRx Pharmaceuticals, Inc. (NRXP) lists 10 active executives. The top listed executive is Jonathan C. Javitt, Co-Founder, Chairman & CEO.
Are NRXP insiders buying or selling?
Recent insider activity shows net buying of $19.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.